By Infinium Global Research Aug, 2020
The global enteral nutrition market was worth USD 4376.5 million in 2016 and it is projected to reach USD 6635.0 million in 2023, expanding at a CAGR of 6.05% between 2017 and 2023. High prevalence of chronic illnesses among the geriatric population and increasing cases of malnutrition, low cost of enteral nutrition products, and a rise in premature birth rates are the primary factor driving the growth in the global market for enteral nutrition. Moreover, and increasing investments in the research and development by the companies operating in this market is expected to accelerate the growth in the enteral nutrition market over the forecast period. On the other hand, the lack of awareness about enteral nutrition is the primary restraining factor hampering the growth in the market over the forecast period. Moreover, complications in the introduction of enteral nutrition to the stomach or small intestines of the patients and safety issues are further likely to restrain the growth in this market over the forecast period. Rising per capita expenditure on healthcare in the emerging markets is likely to create more opportunities for enteral nutrition players over the forecast period.
The report on Global Enteral Nutrition Market covers segments such as product, application, and end user. The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and the Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2015-2023. The report provides profiles of the companies in the global Abbott Laboratories, Nestle S.A., B.Braun Melsungen S.A., Danone S.A., Fresenius Kabi AG, Hormel Foods Corporation, Mead Johnson Nutrition Company, Meiji Holding and Co., Baxter International, Inc., and other companies.